The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Sandoz has agreed to pay $275 million to settle claims that it conspired with competitors to fix prices illegally.Attorneys ...

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

The meeting served as a platform to announce Sandoz Egypt’s new regional head and was held within the framework of strengthening the strategic cooperation between the EDA and Sandoz in the pharmaceuti ...